Treating the full spectrum of dementia with memantine

International Journal of Geriatric Psychiatry

Volumn 18, Issue SUPPL. 1, 2003, Pages

  Winblad, Bengt ^a   Jelic, Vesna ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dementia; Memantine; Treatment

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; ENZYME INHIBITOR; ESTROGEN; GAMMA SECRETASE INHIBITOR; GINKGO BILOBA EXTRACT; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; CEREBROVASCULAR ACCIDENT; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CORRELATION ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; ELDERLY CARE; HEALTH CARE COST; HEART INFARCTION; HUMAN; INSTITUTIONAL CARE; NEUROPSYCHOLOGICAL TEST; PASSIVE IMMUNIZATION; PATHOLOGY; SOCIAL ASPECT; SOCIOECONOMICS; VASCULAR DISEASE; VERTIGO;

AGED; CLINICAL TRIALS; DEMENTIA; DISEASE PROGRESSION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; NEUROPROTECTIVE AGENTS;

EID: 0141595258     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.937     Document Type: Conference Paper

References (35)

1. Aguerro Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. 1998. Prognostic factors in very old demented adults: A seven-year follow-up from a population-based survey in Stockholm. J Am Geriatr Soc 46(4): 444-452.
2. 2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation. J Neurobiol 26(3): 325-338.
3. Bäckman L, Small BJ, Fratiglioni L. 2001. Stability of the preclinical episodic memory deficit in Alzheimer's disease. Brain 124: 96-102.
4. Danysz W, Parsons CG, Möbius HJ, Stöffler A, Quack G. 2000. Neuroprotection and symptomatological action of memantine relevant for Alzheimer's disease - An unified hypothesis on the mechanism of action. Neurotox Res 2: 85-98.
5. Elias MF, Beiser A, Wolf PA, Au R, D'Agostino RB. 2000. The preclinical phase of Alzheimer's disease: A 22-year prospective study of the Framingham cohort. Arch Neurol 57: 808-813.
6. Ferm L. 1974. Behavioural activities in demented geriatric patients. Gerontol Clin 16: 185-194.
7. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
8. Giacobini E. 2001. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs 15(2): 85-91.
9. Giulian D, Haverkamp LJ, Li J, et al. 1995. Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int 27: 119-137.
10. Johansson L. 1998. Care options and service innovations in dementia care. In Health Economics of Dementia. Wimo A, Jönsson B, Karlsson G, Winblad B (eds). John Wiley & Sons: Chichester, UK; 53-66.
11. Jönsson L, Lindgren P, Wimo A, Jönsson B, Winblad B. 1999. Costs of Mini Mental State Examination-related cognitive impairment. Pharmacoeconomics 16(4): 409-416.
12. Kalaria RN, Ballard C. 1999. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 13(Suppl. 3): S115-S1123.
13. Klegeris A, McGeer PL. 1997. Beta amyloid protein enhances nacrophage production of oxygen free radicals and glutamate. J Neurosci Res 49: 229-235.
14. Kosunen O, Soininen H, Paljärvi L, Heinonen O, Talsniemi S, Riekkinen PJ, Sr. 1996. Diagnostic accuracy of Alzheimer's disease: A neuropathological study. Acta Neuropathol 91: 185-193.
15. Mattson MP, Goodmann Y. 1995. Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res 676(1): 219-224.
16. Möbius HJ, Stöffler A. 2002. New approaches to clinical trials in vascular dementia: Memantine in small vesell disease. Cerebrovasc Dis 13(Suppl. 2): 61-66.
17. Orgogozo JM, Forette F (for the MMM 300 group). 2000. Efficacy of memantine in mild to moderate vascular dementia (the MMM 300 trial). Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy [Abstract].
18. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. 1999. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56(3): 303-308.
19. Reisberg B, Windscheif U, Ferris SH, Hingorani VH, Stoeffler A, Moebius HJ. 2000. Memantine in moderately severe to severe Alzheimer's disease (AD): Results of a placebo-controlled 6-month trial. Neurobiol Aging 21(1S): S275 [Abstract].
20. Reisberg B, Doody R, Stöffler A et al. 2003. for the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348: 1333-1341.
21. Rockwood K. 1997. Lessons from mixed dementia. Int Psychogeriatrics 9: 245-249.
22. Snowdown DA, Grenier LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. 1997. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277: 813-817.
23. Topper R, Gehrmann J, Banati R, et al. 1995. Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol (Berl) 89(1): 23-28.
24. Van Der Kam P, Mol F, Wimmers MFHC. Beoordelingschaal voor oudere patienten (BOP). Van Loghum Slaterus: The Netherlands.
25. Van Der Kam P, Hoeksma BH. 1989. The usefulness of BOP and SIVIS (ADL and behaviour rating scales) for the estimation of workload in psychogeriatric nursing home. Results of a time-standard study. Tijdschr Gerontol Geriatr 20: 159-166.
26. Von Strauss E, Viitanen M, De Ronchi D, Winblad B, Fratiglioni L. 1999. Aging and the occurrence of dementia: Findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol 56(5): 587-592.
27. Visser PJ. 2000. Predictors of Alzheimer type dementia in subjects with mild cognitive impairments. Doctoral thesis. University Press Maastricht.
28. Wilcock G. 2000. Cognitive improvement by memantine in a placebo-controlled trial in mild to moderate vascular dementia (the MMM 500 trial). Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy [Abstract].
29. Wahlund L-O, Basun H, Almkvist O, et al. 1999. A follow-up study of the family with Swedish APP 670/671 Alzheimer's disease mutation. Dement Geriatr Cogn Disorder 10: 526-533.
30. Wilcock G, Möbius HJ, Stöffler A on behalf of the MMM 500 group. 2002. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol 17: 297-305.
31. Wimo A, Karlsson G, Sandman PO, Corder L, Winblad B. 1997. Costs of illness due to dementia in Sweden. Int J Geriater Psychiatry 12: 857-861.
32. Winblad B, Engedal K, Soininen H, et al. 2001. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489-495.
33. Winblad B, Poritis N. 1999. Memantine in severe dementia, results of the M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 14(2): 135-146.
34. Winblad B, Möbius HJ, Stöffler A J. 2002. Glutamate receptors as a target for Alzheimer's disease - Are clinical results supporting the hope? J Neural Transm 62(Suppl): 217-225.
35. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. 2000. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzime A reductase inhibitors. Arch Neurol 57: 1439-1443.